Jump to content

Drilldown: Medicines

Choose a table:

Medicines (732)

Medicines > classes: [[:Category:Glucocorticoids|Glucocorticoid]]

& fda max: ICS ~1280 mcg/d; intranasal 256 mcg/d; Entocort 9 mg/d standard

Use the filters below to narrow your results.

Pulmicort (inhaled), Rhinocort (intranasal), Entocort EC and Uceris (enteric-coated oral for IBD), Symbicort (with formoterol) (1)

None (1)

'"`UNIQ--vote-0000099F-QINU`"', '"`UNIQ--vote-000009A0-QINU`"', '"`UNIQ--vote-000009A1-QINU`"', '"`UNIQ--vote-000009A2-QINU`"', '"`UNIQ--vote-000009A3-QINU`"', '"`UNIQ--vote-000009A4-QINU`"' (1)

ICS Pulmicort Flexhaler 180-360 mcg BID; intranasal Rhinocort 64 mcg/spray, 1-2 sprays/nostril daily; Entocort EC 9 mg PO daily for active Crohn's; Symbicort 80/4.5 or 160/4.5 mcg, 2 puffs BID (1)

Pulmicort Flexhaler DPI 90, 180 mcg/dose; Pulmicort Respules 0.25, 0.5, 1 mg/2 mL nebulized; Rhinocort intranasal 32 mcg/spray; Entocort EC 3 mg capsules; Uceris 9 mg ER tablets and rectal foam (1)

Inhaled (1) · intranasal (1) · nebulized (1) · oral (enteric-coated (1) · rectal foam) (1)

Inhaled: bronchial effect 1-2 weeks; oral GI effect 1-2 weeks (1)

12-24 hours (1)

~2-3.6 hours (plasma)'"`UNIQ--ref-000009A5-QINU`"' (1)

~6-13% inhaled lung deposition; ~10% oral (Entocort EC; extensive first-pass via CYP3A4 — this is the basis of the favorable hepatic-targeted local-effect profile in IBD)'"`UNIQ--ref-000009A6-QINU`"' (1)

Long the preferred ICS in pregnancy (Pulmicort) due to the most pregnancy data among the class.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

OTC (intranasal Rhinocort Allergy) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1)

Showing below up to 1 result in range #1 to #1.

B

Budesonide

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"